SanFran, thanks for the repost of the pooled Sustain and Assure data.  Saved me from going and looking it up myself :).  To me what was sorely missing from the NR this morning was the summary of eGFR data.  To me, defining the CKD market opportunity in a NR without explaining how and why RVX has potential to enter the market is an opportunity missed. ie in terms of eGFR reflecting improving kidney function.  Come on RVX IR step it up, connect the dots for the average investor!!!